Granulomatous mastitis (GM) is a rare inflammatory breast disease primarily affecting reproductive-aged women with a history of breastfeeding. Within GM lesions, Corynebacterium kroppenstedtii has frequently been isolated, suggesting it may play a significant role in the development of GM. It is important to develop the novel therapeutic regimen to fight against the Corynebacterium kroppenstedtii infection. In our study, the combination of vancomycin and the lipid-lowering drug Tetrahydrolipstatin (THL) exhibited a synergistic effect against bacteria. Proteomic analysis revealed that potential targets of THL are involved in intermediary metabolism, cellular respiration, lipid metabolism, signaling pathways, virulence, and detoxification and adaptation processes. The combination of THL and vancomycin could be a novel therapeutic regimen to enhance clinical outcomes and reduce the recurrence of GM.
Yang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: